Radiotherapy of primary malignant brain tumors

Larson, David A.; Wara, William M.

doi:10.1002/(sici)1098-2388(199801/02)14:1<34::aid-ssu5>3.0.co;2-3

Cited by 18 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A nucleoside analogue of pentose sugar was approved by USA, Nelarabine ( D ), for treatment of T‐cell malignancy [14] . Later on, Japan approved a purine nucleoside of pentose sugar, Forodesine ( E ) as anticancer drug for treatment of acute lymphoblastic leukemia [15] …”

Section: Introductionmentioning

confidence: 99%

Base‐Induced Annulation of Glycal‐Derived α‐iodopyranone with 2‐Aminopyrimidinones: Access to Chiral Imidazopyrimidinones

Mishra,

Tiwari,

Khanna

et al. 2024

Eur J Org Chem

View full text Add to dashboard Cite

A simple, environmentally benign and catalyst‐free method for the synthesis of chirally enriched imidazo[1,2‐a]pyrimidinone glycohybrids has been successfully developed. The protocol is based on a base‐induced annulation of α‐iodo‐pyranone with Michael addition of 2‐aminopyrimidinones followed by intramolecular nucleophilic substitution reaction. The privilege of this method includes mild reaction conditions, eco‐friendly solvent and a transition metal‐free approach. Moreover, using straightforward simple methods, this reaction method exhibits a broad range of substrate scope and remarkable tolerance toward various functional groups.

show abstract

Section: Introductionmentioning

confidence: 99%

Base‐Induced Annulation of Glycal‐Derived α‐iodopyranone with 2‐Aminopyrimidinones: Access to Chiral Imidazopyrimidinones

Mishra,

Tiwari,

Khanna

et al. 2024

Eur J Org Chem

View full text Add to dashboard Cite

show abstract

“…High-grade gliomas are the most common and aggressive primary brain tumors (DeAngelis et al 1998, Larson and Wara 1998, Black 1998, Breg et al 2003, Lonardi et al 2005, DeAngelis 2005, Stupp and Weber 2005, Mason and Cairncross 2005. Surgery and radiotherapy constitute the initial treatments for malignant gliomas.…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, the recurrence of the tumor, even after radical excision, makes postoperative therapeutic strategies such as radiotherapy and chemotherapy a necessity to reduce tumor progression. Radiation therapy is known to be an effective postoperative treatment for malignant gliomas, as it increases the survival time for patients compared to surgery alone (Larson andWara 1998, Berg et al 2003). Most commonly, a radiation dose of 60 Gy (1 Gy is 1 J kg −1 ) in 2 Gy daily fractions is delivered using multiple co-planar external high energy beams to a volume that encompasses the primary tumor (or resection cavity) and a margin of adjacent normal brain deemed at a high risk of harboring subclinical disease (Lonardi et al 2005).…”

Section: Introductionmentioning

confidence: 99%

Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy

et al. 2007

View full text Add to dashboard Cite

Gliomas, the most common primary brain tumors, are diffusive and highly invasive. The standard treatment for brain tumors consists of a combination of surgery, radiation therapy and chemotherapy. Over the past few years, mathematical models have been applied to study untreated and treated brain tumors. In an effort to improve treatment strategies, we consider a simple spatio-temporal mathematical model, based on proliferation and diffusion, that incorporates the effects of radiotherapeutic and chemotherapeutic treatments. We study the effects of different schedules of radiation therapy, including fractionated and hyperfractionated external beam radiotherapy, using a generalized linear quadratic (LQ) model. The results are compared with published clinical data. We also discuss the results for combination therapy (radiotherapy plus temozolomide, a new chemotherapy agent), as proposed in recent clinical trials. We use the model to predict optimal sequencing of the postoperative (combination of radiotherapy and adjuvant, neo-adjuvant or concurrent chemotherapy) treatments for brain tumors.

show abstract

A concurrent ultra‐fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma

Beauchesne

Quillien

Faure

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients. A phase II study opened; patients over 18 years of age who were able to give informed consent and had histologically proven, newly diagnosed inoperable diagnosed and supratentorial glioblastoma were eligible. Three doses of 0.75 Gy spaced apart by at least 4 hr were delivered daily, 5 days a week for six consecutive weeks for a total of 67.5 Gy. Chemotherapy was administered during the same period, which consisted of temozolomide given at a dose of 75 mg/m 2 for 7 days a week. After a 4-week break, chemotherapy was resumed for up to six cycles of adjuvant temozolomide treatment, given every 28 days, according to the standard 5-day regimen. Tolerance and toxicity were the primary endpoints; survival and progression-free survival were the secondary endpoints. In total, 40 patients were enrolled in this study, 29 men and 11 women. The median age was 58 years, and the median Karnofsky performance status was 80. The concomitant ultra-fractionated radiotherapy and temozolomide treatment was well tolerated. Complete responses were seen in four patients, and partial responses were reported in seven patients. The median survival from the initial diagnosis was 16 months. Several long-term survivors were noted. Concurrent ultra-fractionated radiation therapy and temozolomide treatment are well accepted by the patients. The results showed encouraging survival rates for these unfavorable patients.Glioblastoma (GBM) is the most common primary brain tumor in adults and is characterized by a high rate of local recurrences because of its intrinsic radioresistance. 1-4 Indeed, GBM is considered one of the most radioresistant tumors.

show abstract

Radiotherapy of primary malignant brain tumors

Cited by 18 publications

References 50 publications

Base‐Induced Annulation of Glycal‐Derived α‐iodopyranone with 2‐Aminopyrimidinones: Access to Chiral Imidazopyrimidinones

Base‐Induced Annulation of Glycal‐Derived α‐iodopyranone with 2‐Aminopyrimidinones: Access to Chiral Imidazopyrimidinones

Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy

A concurrent ultra‐fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma

Contact Info

Product

Resources

About